Relevant bibliographies by topics / Kynurenine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Kynurenine'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Kynurenine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Kynurenine"

1

Maget, Alexander, Martina Platzer, Susanne A. Bengesser, et al. "Differences in Kynurenine Metabolism During Depressive, Manic, and Euthymic Phases of Bipolar Affective Disorder." Current Topics in Medicinal Chemistry 20, no. 15 (2020): 1344–52. http://dx.doi.org/10.2174/1568026619666190802145128.

Full text
Abstract:
Background & Objectives: The kynurenine pathway is involved in inflammatory diseases. Alterations of this pathway were shown in psychiatric entities as well. The aim of this study was to determine whether specific changes in kynurenine metabolism are associated with current mood symptoms in bipolar disorder. Methods: Sum scores of the Hamilton Depression Scale, Beck Depression Inventory, and Young Mania Rating Scale were collected from 156 bipolar individuals to build groups of depressive, manic and euthymic subjects according to predefined cut-off scores. Severity of current mood symptoms
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Yiquan, and Gilles J. Guillemin. "Kynurenine Pathway Metabolites in Humans: Disease and Healthy States." International Journal of Tryptophan Research 2 (January 2009): IJTR.S2097. http://dx.doi.org/10.4137/ijtr.s2097.

Full text
Abstract:
Tryptophan is an essential amino acid that can be metabolised through different pathways, a major route being the kynurenine pathway. The first enzyme of the pathway, indoleamine-2,3-dioxygenase, is strongly stimulated by inflammatory molecules, particularly interferon gamma. Thus, the kynurenine pathway is often systematically up-regulated when the immune response is activated. The biological significance is that 1) the depletion of tryptophan and generation of kynurenines play a key modulatory role in the immune response; and 2) some of the kynurenines, such as quinolinic acid, 3-hydroxykynu
APA, Harvard, Vancouver, ISO, and other styles
3

Badawy, Abdulla A. B., and Samina Bano. "Tryptophan Metabolism in Rat Liver after Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors." International Journal of Tryptophan Research 9 (January 2016): IJTR.S38190. http://dx.doi.org/10.4137/ijtr.s38190.

Full text
Abstract:
Rat liver tryptophan (Trp), kynurenine pathway metabolites, and enzymes deduced from product/substrate ratios were assessed following acute and/or chronic administration of kynurenic acid (KA), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), Trp, and the kynureninase inhibitors benserazide (BSZ) and carbidopa (CBD). KA activated Trp 2,3-dioxygenase (TDO), possibly by increasing liver 3-HAA, but inhibited kynurenine aminotransferase (KAT) and kynureninase activities with 3-HK as substrate. 3-HK inhibited kynureninase activity from 3-HK. 3-HAA stimulated TDO, but inhibited kynuren
APA, Harvard, Vancouver, ISO, and other styles
4

Majláth, Zsófia, and László Vécsei. "A kinureninrendszer és a stressz." Orvosi Hetilap 156, no. 35 (2015): 1402–5. http://dx.doi.org/10.1556/650.2015.30246.

Full text
Abstract:
The kynurenine pathway is the main route of tryptophan degradation which gives rise to several neuroactive metabolites. Kynurenic acid is an endogenous antagonist of excitatory receptors, which proved to be neuroprotective in the preclinical settings. Kynurenines have been implicated in the neuroendocrine regulatory processes. Stress induces several alterations in the kynurenine metabolism and this process may contribute to the development of stress-related pathological processes. Irritable bowel disease and gastric ulcer are well-known disorders which are related to psychiatric comorbidity an
APA, Harvard, Vancouver, ISO, and other styles
5

Hafstad Solvang, Stein-Erik, Jan Erik Nordrehaug, Dag Aarsland, et al. "Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia." International Journal of Tryptophan Research 12 (January 2019): 117864691987788. http://dx.doi.org/10.1177/1178646919877883.

Full text
Abstract:
Introduction: Circulating tryptophan (Trp) and its downstream metabolites, the kynurenines, are potentially neuroactive. Consequently, they could be associated with neuropsychiatric symptoms and cognitive prognosis in patients with dementia. Objective: The objective of this study was to assess associations between circulating kynurenines, cognitive prognosis, and neuropsychiatric symptoms. Methods: We measured baseline serum Trp, neopterin, pyridoxal 5′-phosphate (PLP), and 9 kynurenines in 155 patients with mild dementia (90 with Alzheimer’s disease, 65 with Lewy body dementia). The ratios be
APA, Harvard, Vancouver, ISO, and other styles
6

Gawel, Kinga. "A Review on the Role and Function of Cinnabarinic Acid, a “Forgotten” Metabolite of the Kynurenine Pathway." Cells 13, no. 5 (2024): 453. http://dx.doi.org/10.3390/cells13050453.

Full text
Abstract:
In the human body, the majority of tryptophan is metabolized through the kynurenine pathway. This consists of several metabolites collectively called the kynurenines and includes, among others, kynurenic acid, L-kynurenine, or quinolinic acid. The wealth of metabolites, as well as the associated molecular targets and biological pathways, bring about a situation wherein even a slight imbalance in the kynurenine levels, both in the periphery and central nervous system, have broad consequences regarding general health. Cinnabarinic acid (CA) is the least known trace kynurenine, and its physiologi
APA, Harvard, Vancouver, ISO, and other styles
7

Büki, Alexandra, Gabriella Kekesi, Gyongyi Horvath, and László Vécsei. "A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia." International Journal of Molecular Sciences 22, no. 18 (2021): 10016. http://dx.doi.org/10.3390/ijms221810016.

Full text
Abstract:
Schizophrenia is a neuropsychiatric disorder characterized by various symptoms including autonomic imbalance. These disturbances involve almost all autonomic functions and might contribute to poor medication compliance, worsened quality of life and increased mortality. Therefore, it has a great importance to find a potential therapeutic solution to improve the autonomic disturbances. The altered level of kynurenines (e.g., kynurenic acid), as tryptophan metabolites, is almost the most consistently found biochemical abnormality in schizophrenia. Kynurenic acid influences different types of rece
APA, Harvard, Vancouver, ISO, and other styles
8

Myint, A. M. "Role of Tryptophan-kynurenine Pathway in Depression: Psychopathological Aspect." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70521-8.

Full text
Abstract:
It was reported that cytokines such as IFN-γ reduce the synthesis of 5-HT by stimulating the activity of indoleamine 2,3 dioxygenase (IDO) enzyme which degrades tryptophan to kynurenine. Kynurenine is further metabolized to kynurenic acid (KYNA), 3-hydroxykynurenine (3OHK) and quinolinic acid (QA) by kynurenine aminotransferase (KAT), kynurenine 3-monooxygenase (KMO) and kynureninase. Both KMO and kynureninase are also shown to be activated by IFNγ. The 3OHK is neurotoxic apoptotic while QA is the excitotoxic N-methyl-D-aspartate (NMDA) receptor agonist. Conversely KYNA is an antagonist of all
APA, Harvard, Vancouver, ISO, and other styles
9

Szűcs, Edina, Azzurra Stefanucci, Marilisa Pia Dimmito, et al. "Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists." Biomolecules 10, no. 2 (2020): 284. http://dx.doi.org/10.3390/biom10020284.

Full text
Abstract:
Kynurenine (kyn) and kynurenic acid (kyna) are well-defined metabolites of tryptophan catabolism collectively known as “kynurenines”, which exert regulatory functions in host-microbiome signaling, immune cell response, and neuronal excitability. Kynurenine containing peptides endowed with opioid receptor activity have been isolated from natural organisms; thus, in this work, novel opioid peptide analogs incorporating L-kynurenine (L-kyn) and kynurenic acid (kyna) in place of native amino acids have been designed and synthesized with the aim to investigate the biological effect of these modific
APA, Harvard, Vancouver, ISO, and other styles
10

Zakharov, Gennady A., Alexander V. Zhuravlev, Tatyana L. Payalina, Nikolay G. Kamyshev, and Elena V. Savvateeva-Popova. "The influence of D. melanogaster mutations of the kynurenine pathway of tryptophan metabolism on locomotor behavior and expression of genes belonging to glutamatergic and cholinergic systems." Ecological genetics 9, no. 2 (2011): 65–73. http://dx.doi.org/10.17816/ecogen9265-73.

Full text
Abstract:
Disbalance of kynurenines produced by Drosophila mutations of the kynurenine pathway of tryptophan metabolism influences the locomotor behavior in larvae. The most pronounced is the effect of accumulation of kynurenic acid in the mutant cinnabar manifested as sharp reduction of general level of locomotor activity. The mutations seem to act through modulatory influences of kynurenines on signal cascades governed by ionotropic glutamatergic and cholinergic receptors. Expression of receptor genes in the mutants shows age-related changes pointing to gradual evolvement of consequences of kynurenine
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Kynurenine"

1

Milne, Gavin D. S. "Inhibition studies of kynurenine 3-monooxygenase." Thesis, University of St Andrews, 2013. http://hdl.handle.net/10023/4101.

Full text
Abstract:
Kynurenine 3-monooxygenase (K3MO) lies on the kynurenine pathway, the major pathway for the catabolism of L-tryptophan. It converts kynurenine to 3-hydroxy kynurenine. Inhibition of K3MO is important in several neurological diseases and there is evidence that inhibition of K3MO could also be targeted for the prevention of multiple organ failure, secondary to acute pancreatitis. A structure activity relationship based upon the 1,2,4-oxadiazoles motif was carried out which revealed amide 207 as an inhibitor of P. fluorescens K3MO. Further structure activity relationships were developed based upo
APA, Harvard, Vancouver, ISO, and other styles
2

Thevandavakkam, Mathuravani Aaditiyaa. "Deciphering the kynurenine-3-monooxygenase interactome." Thesis, University of Leicester, 2011. http://hdl.handle.net/2381/10070.

Full text
Abstract:
Kynurenine-3-monooxygenase (KMO) is a mitochondrial enzyme in the kynurenine pathway (KP) through which tryptophan is degraded to NAD+. The central KP is altered in neurodegenerative diseases and other CNS disorders. The causative role of KP metabolites has been particularly well studied in the neurodegenerative disorder Huntington’s disease (HD), a fatal adult onset condition inherited in an autosomal dominant manner. In HD, flux in the KP is perturbed such that neurotoxic metabolites (3-hydroxykynurenine and quinolinic acid) of the pathway are increased relative to a neuroprotective metaboli
APA, Harvard, Vancouver, ISO, and other styles
3

Bell, Helen Barbara. "Characterisation of the active site of kynurenine 3-monooxygenase." Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/20397.

Full text
Abstract:
Kynurenine 3-monooxygenase (KMO) is a flavoprotein which has been implicated in Huntington’s disease, Alzheimer’s disease and acute pancreatitis. Recently there has been important research published about this enzyme including the structure of a truncated Saccharomyces cerevisiae KMO enzyme and KMO inhibition studies in animal models of disease. In previous work from this research group the complete Pseudomonas fluorescens KMO enzyme has been successfully crystallised both with and without the substrate, L-kynurenine, from which significant insights were gained into function and the potential
APA, Harvard, Vancouver, ISO, and other styles
4

Wilkinson, Martin. "Structural dynamics and ligand binding in kynurenine-3-monooxygenase." Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/7965.

Full text
Abstract:
Kynurenine 3-monooxygenase is a FAD-dependent aromatic hydroxylase (FAH) which is a widely suggested therapeutic target for controlling the balance of bioactive metabolite levels produced by the mammalian kynurenine pathway (KP). Prior to starting this work no structural information was known for the enzyme, with studies of the human form complicated by the presence of a C-terminal transmembrane helix. The bacterial Pseudomonas fluorescens enzyme (PfKMO) lacks the transmembrane region and has been previously characterised by Crozier-Reabe and Moran [1, 2]. Therefore PfKMO, which shares 32 % se
APA, Harvard, Vancouver, ISO, and other styles
5

Owe-Young, Robert School of Medicine UNSW. "Kynurenine pathway metabolism at the blood-brain barrier." Awarded by:University of New South Wales. School of Medicine, 2006. http://handle.unsw.edu.au/1959.4/26183.

Full text
Abstract:
A major product of HIV-infected and cytokine-stimulated monocytic-lineage cells is quinolinic acid (QUIN), a neurotoxic metabolite of the kynurenine pathway (KP) of L-tryptophan (L-Trp) metabolism. Despite the large number of neurotoxins found in HIV patients with AIDS Dementia Complex (ADC), only QUIN correlates with both the presence and severity of ADC. With treatment, cerebrospinal fluid (CSF) QUIN concentrations decrease proportionate to the degree of clinical and neuropsychological improvement. As endothelial cells (EC) of the blood-brain barrier (BBB) are the first brain-associated cell
APA, Harvard, Vancouver, ISO, and other styles
6

Taylor, Mark Robert Duncan. "High-resolution structural studies of kynurenine 3-monooxygenase." Thesis, University of Edinburgh, 2018. http://hdl.handle.net/1842/28913.

Full text
Abstract:
The kynurenine pathway produces NAD+ from L-tryptophan. Metabolites known as the kynurenines are produced within the pathway. The effects of the kynurenines have been associated with a number of diseases including cancer, Alzheimer’s disease, Huntington’s disease, and acute pancreatitis. Kynurenine monooxygenase (KMO) is an enzyme that catalyses the conversion of L-kynurenine to 3-hydroxy-L-kynurenine, the downstream product of which is the neurotoxic quinolinic acid. L-kynurenine is positioned at a branching point within the pathway. Metabolism via KMO leads to quinolinic acid production wher
APA, Harvard, Vancouver, ISO, and other styles
7

Swaih, Aisha Mahmod O. "Functional and localization studies of human kynurenine 3-monooxygenase." Thesis, University of Leicester, 2016. http://hdl.handle.net/2381/37835.

Full text
Abstract:
Kynurenine 3-monooxygensae (KMO) is an outer mitochondrial membrane protein which plays a critical regulatory role in the kynurenine pathway (KP), catalysing the production of 3-hydroxykynurenine (3-HK). Increased KMO activity likely contributes to the excitotoxicity seen in neurodegenerative disorders by elevating the levels of the neurotoxic KP metabolites 3-HK and quinolinic acid. Studies employing models of Huntington’s disease (HD) have shown that inhibition of KMO is neuroprotective, making KMO a potential therapeutic target for this disorder. This study interrogates the subcellular loca
APA, Harvard, Vancouver, ISO, and other styles
8

Kolodziej, Lukasz. "An investigation of the kynurenine pathway in experimental arthritis." Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/9641.

Full text
Abstract:
The kynurenine pathway is a catabolic biochemical pathway responsible for degradation of tryptophan, an essential amino acid. As a consequence, biologically active molecules, kynurenines, are produced. These chemical entities can influence immune responses. Previously, it has been shown that pharmacological inhibition of the initial step on the pathway increases the severity of collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis. In contrast, treatment with kynurenine, a major by product of tryptophan degradation, effectively ameliorated the disease. This project was base
APA, Harvard, Vancouver, ISO, and other styles
9

Skouras, Christos. "Kynurenine metabolism and organ dysfunction in human acute pancreatitis." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/28898.

Full text
Abstract:
BACKGROUND: Acute pancreatitis (AP) is a sterile initiator of systemic inflammation that can trigger multiple organ dysfunction syndrome (MODS). In the acute phase of AP, the kynurenine pathway of tryptophan metabolism plays an important role in the genesis of AP-MODS in experimental animal models, but it is unknown whether the pathway is activated in human AP. Human data are required to support the rationale for kynurenine 3- monooxygenase (KMO) inhibition as a treatment for AP-MODS and reinforce the translational potential. Additionally, as respiratory dysfunction is frequent in severe AP, t
APA, Harvard, Vancouver, ISO, and other styles
10

Urenjak, Jutta A., and Tihomir P. Obrenovitch. "Accumulation of quinolinic acid with euro-inflammation: does it mean excitotoxicity?" Thesis, Kluwer Academic, Plenum Publishers, New York, 2003. http://hdl.handle.net/10454/2833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Kynurenine"

1

Schwarcz, Robert, Simon N. Young, and Raymond R. Brown, eds. Kynurenine and Serotonin Pathways. Springer New York, 1991. http://dx.doi.org/10.1007/978-1-4684-5952-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mittal, Sandeep, ed. Targeting the Broadly Pathogenic Kynurenine Pathway. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-11870-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Robert, Schwarcz, Young Simon N, and Brown Raymond R, eds. Kynurenine and serotonin pathways: Progress in tryptophan research. Plenum Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

W, Stone T., ed. Quinolinic acid and the kynurenines. CRC Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rickards, Edward Hugh Galbraith. Plasma kynurenine tryptophan metabolites and associated substances in Gilles de la Tourette's Syndrome. University of Birmingham, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mirza, Sarwarbeg. The hepatic and the peripheral metabolism of tryptophan via the kynurenine pathway in children with biliary atresiaand with orthotopic liver transplant: The assessment of the relationship between the levels of the kynurenine metabolites, neopterin, biopterin and liver function tests. University of Surrey, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Naleem, Wazeer A. A study of urinary kynurenine metabolites in pre-pubertal, pubertal and post-pubertal male offsprings of families with family history negative and family history positive of alcoholism. University of Surrey, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lázló, Vécsei, ed. Kynurenines in the brain: From experiments to clinics. Nova Science Publishers, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lapin, Izjaslav P. The neuroactivities of kynurenines: Stress, anxiety, depression, alcoholism, epilepsy : the 2000 Oswald Schmiedeberg lecture. Tartu Ülikool, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Young, Simon N., and Raymond R. Brown. Kynurenine and Serotonin Pathways. Island Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Kynurenine"

1

Schomburg, Dietmar, and Dörte Stephan. "Kynurenine 3-monooxygenase." In Enzyme Handbook. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-57942-4_91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schomburg, Dietmar, and Dörte Stephan. "Kynurenine-oxoglutarate transaminase." In Enzyme Handbook 13. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-59176-1_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schomburg, Dietmar, and Dörte Stephan. "Kynurenine-glyoxylate transaminase." In Enzyme Handbook 13. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-59176-1_98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Okuno, E., and R. Kido. "Kynureninase and Kynurenine 3-Hydroxylase in Mammalian Tissues." In Advances in Experimental Medicine and Biology. Springer New York, 1991. http://dx.doi.org/10.1007/978-1-4684-5952-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Minatogawa, Y., C. Kawai, S. Hatada, and M. Sato. "Liver Specific Kynurenine (Alanine)." In Advances in Experimental Medicine and Biology. Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0381-7_73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schomburg, Dietmar, and Dörte Stephan. "Kynurenine 7, 8-hydroxylase." In Enzyme Handbook. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-57942-4_154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Majláth, Zsófia, Levente Szalárdy, Dénes Zádori, et al. "Neuroprotection by Kynurenine Metabolites." In Handbook of Neurotoxicity. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-15080-7_165.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rudzite, V., and E. Jurika. "Kynurenine and Lipid Metabolism." In Advances in Experimental Medicine and Biology. Springer New York, 1991. http://dx.doi.org/10.1007/978-1-4684-5952-4_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Majláth, Zsófia, Levente Szalárdy, Dénes Zádori, et al. "Neuroprotection by Kynurenine Metabolites." In Handbook of Neurotoxicity. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-5836-4_165.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Weil-Fugazza, J. "Endogenous Kynurenine Derivatives and Pain." In Advances in Experimental Medicine and Biology. Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0381-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Kynurenine"

1

Gosker, Harry R., Gerard Clarke, John F. Cryan, and Annemie M. Schols. "Impaired skeletal muscle kynurenine metabolism in patients with COPD." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa940.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tharawadeephimuk, Waranan, Chaiyavat Chaiyasut, Sasithorn Sirilun, and Phakkharawat Sittiprapaporn. "Preliminary Study of Probiotics and Kynurenine Pathway in Autism Spectrum Disorder." In 2019 16th International Conference on Electrical Engineering/Electronics, Computer, Telecommunications and Information Technology (ECTI-CON). IEEE, 2019. http://dx.doi.org/10.1109/ecti-con47248.2019.8955380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Triplett, Todd A., Kendra Triplett, Everett Stone, et al. "Abstract 5571: Immune-checkpoint inhibition via enzyme-mediated degradation of kynurenine." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5571.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pinto, Sheena, Christoph Steeneck, Michael Albers, et al. "Abstract 1210: Targeting the IDO1-Kynurenine-AhR pathway for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pinto, Sheena, Christoph Steeneck, Michael Albers, et al. "Abstract 1210: Targeting the IDO1-Kynurenine-AhR pathway for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Botticelli, Andrea, Bruna Cerbelli, Luana Lionetto, et al. "Abstract 5705: The key role of kynurenine in anti-PD-1 failure." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Breda, Carlo, Aisha M. Swaih, Mariaelena Repici, and Flaviano Giorgini. "A29 Kynurenine 3-monooxygenase interacts with huntingtin at the outer mitochondrial membrane." In EHDN 2018 Plenary Meeting, Vienna, Austria, Programme and Abstracts. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/jnnp-2018-ehdn.27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Poulain-Godefroy, Odile, Mélina Le Roux, Gwenola Kervoaze, Anais Ollivier, Muriel Pichavant, and Philippe Gosset. "Kynurenine pathway as a modulator of inflammation in COPD and its exacerbations." In ERS Lung Science Conference 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/23120541.lsc-2022.61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wangpaichitr, Medhi, Chunjing Wu, Dan JM Nguyen, Ying-Ying Li, Lynn G. Feun, and Niramol Savaraj. "Abstract 5478: Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5478.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bessede, Alban, Antoine Italiano, Assia Chaïbi, et al. "Abstract 5716: Functional evidence for an immunosuppressive role of kynurenine in cancer patients." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Kynurenine' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography